RiVive® is an FDA-approved over-the-counter (OTC) emergency treatment for opioid overdose
Order RiVive for direct shipment from Harm Reduction Therapeutics, or through many other delivery options we have available including Remedy Alliance/For The People (RA), Cardinal Health, Cencora, McKesson, and A2A Alliance Pharmaceuticals.
It is used to “revive” someone during an overdose from many prescription opioid-containing pain medications or street drugs. This medicine can save a life.
RiVive was developed by Harm Reduction Therapeutics, Inc., a 501(c)(3) non-profit pharmaceutical company whose mission is to save lives that would otherwise be lost to opioid overdose. To make a charitable contribution to help us continue our mission, click here.
HOW RiVive WORKS
Naloxone is the active ingredient in RiVive nasal spray. Naloxone quickly reverses an overdose by blocking the effects of opioids. It can restore normal breathing within 2 to 3 minutes in a person whose breath has slowed, or even stopped, as a result of opioid overdose. More than one dose of naloxone may be required.
Naloxone’s approval in 1971 led to increasingly widespread use as standard equipment in emergency medicine in the 1980s before being distributed by harm reduction organizations in the 1990s as part of their public health initiatives. Intranasal naloxone is a well-established way to provide safe, rapid, and effective reversals of opioid overdoses.
WE HAVE ONE MISSION – TO SAVE AS MANY LIVES AS POSSIBLE
With additional funding partners, Harm Reduction Therapeutics is focused on supplying RiVive to communities who need it most by donating at least 10% of projected annual production to underfunded harm reduction organizations.
HOW TO GET NALOXONE
U.S. Harm Reduction organizations, state and other government procurement functions can order FDA-approved RiVive for the emergency treatment of opioid overdose by contacting (888) 412-7454 or by emailing sales@harmreductiontherapeutics.org.
RiVive, which can save lives, will be available at cost or less, with its initial selling price set at $36 per twin pack. This price covers the hard costs (inactive ingredients, devices, vials) and production, packaging, testing, and transportation costs (~92% of the price) plus the virtual organization’s minimal administration costs (~8%)